Celecoxib, the first FDA approved COX-2-selective inhibitor, initially developed for the clinical treatment of rheumatoid arthritis and relief of inflammation and pain, has also been used for the treatment of familial adenomatous polyposis [55,56,57,58]. The gene discussed is PTGS2; the disease is rheumatoid arthritis.